Results

Total Results: 543 records

Showing results for "anticoagulant prophylaxis".

  1. PSI 90 Fact Sheet (pdf file)

    qualityindicators.ahrq.gov/News/PSI90_Factsheet_FAQ_V1.pdf
    August 31, 2016 - 12 events in this population may be less preventable due to safety concerns with pharmacological prophylaxis
  2. Psi90 Factsheet Faq (pdf file)

    qualityindicators.ahrq.gov/News/PSI90_Factsheet_FAQ.pdf
    August 31, 2016 - 12 events in this population may be less preventable due to safety concerns with pharmacological prophylaxis
  3. effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
    January 01, 2006 - of spine; Fever; Juvenile rheumatoid arthritis; Myocardial infarction; Myocardial infarction; Prophylaxis … flurbiprofen Elimination half-life range- 3.36 to 11.55 hrs Constricted pupil, intraoperative prophylaxisagents Rofecoxib=35.3% Celecoxib=21.9% p<0.0001 (a) Cardiovascular TE (b) Cerebrovascular … agents (a) 1.04 (0.50, 2.17) (b) 1.43 (0.86, 2.38) (c) 0.36 (0.01, 1.34) n/a (a) increased risk … associated with age, sex, cc aspirin use, cc antiplatelet/anticoagulant agents (b) increased risk
  4. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
    January 01, 2006 - of spine; Fever; Juvenile rheumatoid arthritis; Myocardial infarction; Myocardial infarction; Prophylaxis … flurbiprofen Elimination half-life range- 3.36 to 11.55 hrs Constricted pupil, intraoperative prophylaxisagents Rofecoxib=35.3% Celecoxib=21.9% p<0.0001 (a) Cardiovascular TE (b) Cerebrovascular … agents (a) 1.04 (0.50, 2.17) (b) 1.43 (0.86, 2.38) (c) 0.36 (0.01, 1.34) n/a (a) increased risk … associated with age, sex, cc aspirin use, cc antiplatelet/anticoagulant agents (b) increased risk
  5. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety/vol4/Kizer1.pdf
    April 01, 2004 - procedure for his or her risk of surgical site infection (SSI), and implement appropriate antibiotic prophylaxis … all “high alert” drugs (e.g., intravenous adrenergic agonists and antagonists, chemotherapy agents, anticoagulants
  6. www.qualitymeasures.ahrq.gov/research/findings/final-reports/ssi/ssiapm.html
    April 01, 2018 -     1 intra-op drugs on paper anesthesia record D Electronic 1     Peri-Op VTE Prophylaxis
  7. ce.effectivehealthcare.ahrq.gov/research/findings/final-reports/ssi/ssiapm.html
    April 01, 2018 -     1 intra-op drugs on paper anesthesia record D Electronic 1     Peri-Op VTE Prophylaxis
  8. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/hai/clabsi-tools/vascular-access-device-policy.pdf
    March 01, 2008 - INR or a PTT ratio > 1.3, platelets < 50K) or if patient is on therapeutic dosing of thrombolytics/anticoagulants … The nurse may remove central VAD for patients on anticoagulants for Venous Thromboembolism (VTE) Prophylaxis … The following are considered prophylactic dosing for VTE: Drug Usual prophylaxis dose Heparin 5000
  9. www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety-2/vol2/Advances-Ehringer_17.pdf
    February 08, 2008 - include information beyond what the physician might initially consider, such as venous thromboembolism prophylaxis … Venous thromboembolism prophylaxis Sequential compression devices for bilateral lower extremities … Adding DVT prophylaxis, vaccination status, smoking counseling, patient education, etc Adding safety
  10. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety-2/vol2/Advances-Ehringer_17.pdf
    February 08, 2008 - include information beyond what the physician might initially consider, such as venous thromboembolism prophylaxis … Venous thromboembolism prophylaxis Sequential compression devices for bilateral lower extremities … Adding DVT prophylaxis, vaccination status, smoking counseling, patient education, etc Adding safety
  11. effectivehealthcare.ahrq.gov/sites/default/files/related_files/hemophilia-dental-rapid-response.pdf
    July 01, 2024 - In dental procedures that required local anesthesia, it was recommended that children on routine prophylaxis … for factor therapy differed for adults versus children—it was recommended that children on routine prophylaxis … PubMed search history on November 30, 2023 Search Number Query Results 1 "Dental Prophylaxis"[ … 3] OR "dental extraction"[Title/Abstract:~3] OR "dental extractions"[Title/Abstract:~3] OR "dental prophylaxis … Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia
  12. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/hemophilia-dental-rapid-response.pdf
    July 01, 2024 - In dental procedures that required local anesthesia, it was recommended that children on routine prophylaxis … for factor therapy differed for adults versus children—it was recommended that children on routine prophylaxis … PubMed search history on November 30, 2023 Search Number Query Results 1 "Dental Prophylaxis"[ … 3] OR "dental extraction"[Title/Abstract:~3] OR "dental extractions"[Title/Abstract:~3] OR "dental prophylaxis … Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia
  13. digital.ahrq.gov/sites/default/files/docs/medication-management-elderly-slides-081811.pdf
    August 18, 2011 - 100 120 Drug interactions Inadequate monitoring Failure to act on monitoring Known allergy No prophylaxis
  14. digital.ahrq.gov/sites/default/files/docs/publication/r18hs017010-bailey-final-report-2011.pdf
    January 01, 2011 - previous work we have shown that ambulatory ADEs related to high-alert medications – particularly anticoagulants … started during hospitalization may be continued without adequate outpatient monitoring (e.g., oral anticoagulants … definition: “an effect which is noxious and unintended, and which occurs at doses used in man for prophylaxis … hazardous medications that are used heavily in adults, but much less frequently in children – such as anticoagulants
  15. Layout 1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_executive.pdf
    May 01, 2010 - Pediatric cardiac surgery A total of 40 patients received rFVIIa prophylaxis in one poor quality RCT
  16. Layout 1 (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_executive.pdf
    May 01, 2010 - Pediatric cardiac surgery A total of 40 patients received rFVIIa prophylaxis in one poor quality RCT
  17. www.uspreventiveservicestaskforce.org/home/getfilebytoken/xUc_vXf7323faUQY7SePhT
    January 01, 2002 - At that time, the Task Force found insufficient evidence to recommend for or against routine aspirin prophylaxis … Concomitant use of other nonsteroidal anti-inflammatory agents or anticoagulants further increased risk … Aspirin for the Primary Prevention of Cardiovascular Events 24 Adults without known CVD Aspirin prophylaxis
  18. effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_executive.pdf
    April 01, 2012 - concomitant prescription drugs from, on average, 5.9 different drug classes for primary and secondary prophylaxis … : 40-55 years Mixed gender Unclear CHD risk 6-25 weeks treatment INR Vitamin K (150 μg /day) + Anticoagulants … combination with antiplatelet agents (acetylsalicylic acid,65,66 clopidogrel,67 or ticlopidine68), an anticoagulant … Overall evidence indicates that supplementation with vitamin K may improve the stability of anticoagulant … or withdrawal due to adverse events.41 This study recruited 70 participants with indications for anticoagulant
  19. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/dietary-supplements_executive.pdf
    April 01, 2012 - concomitant prescription drugs from, on average, 5.9 different drug classes for primary and secondary prophylaxis … : 40-55 years Mixed gender Unclear CHD risk 6-25 weeks treatment INR Vitamin K (150 μg /day) + Anticoagulants … combination with antiplatelet agents (acetylsalicylic acid,65,66 clopidogrel,67 or ticlopidine68), an anticoagulant … Overall evidence indicates that supplementation with vitamin K may improve the stability of anticoagulant … or withdrawal due to adverse events.41 This study recruited 70 participants with indications for anticoagulant
  20. digital.ahrq.gov/sites/default/files/docs/citation/r01hs026732-usher-final-report-2023.pdf
    January 01, 2023 - ; 95% CI, 0.66-0.99) and the use of COVID-19–specific therapeutics including deep vein thrombosis prophylaxis